Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionchromatin binding

SREBF2 TRIM33 MLLT10 NELFA HCFC1

1.48e-05739105GO:0003682
GeneOntologyBiologicalProcesspositive regulation of transcription by RNA polymerase II

SREBF2 ATF1 USF3 MLLT10 NELFA HCFC1

1.54e-051390106GO:0045944
GeneOntologyCellularComponentchromatin

SREBF2 ATF1 TRIM33 HCFC1

5.52e-031480114GO:0000785
DomainZinc_finger_PHD-type_CS

TRIM33 MLLT10

6.43e-0465112IPR019786
DomainPHD

TRIM33 MLLT10

8.55e-0475112PF00628
DomainZnf_PHD-finger

TRIM33 MLLT10

9.48e-0479112IPR019787
DomainPHD

TRIM33 MLLT10

1.20e-0389112SM00249
DomainZnf_PHD

TRIM33 MLLT10

1.25e-0391112IPR001965
DomainZF_PHD_2

TRIM33 MLLT10

1.37e-0395112PS50016
DomainZF_PHD_1

TRIM33 MLLT10

1.40e-0396112PS01359
DomainHLH

SREBF2 USF3

1.86e-03111112PF00010
DomainHLH

SREBF2 USF3

2.03e-03116112SM00353
DomainBHLH

SREBF2 USF3

2.06e-03117112PS50888
DomainbHLH_dom

SREBF2 USF3

2.10e-03118112IPR011598
DomainZnf_FYVE_PHD

TRIM33 MLLT10

3.23e-03147112IPR011011
Domain-

TRIM33 MLLT10

2.75e-024491123.30.40.10
DomainZnf_RING/FYVE/PHD

TRIM33 MLLT10

2.86e-02459112IPR013083
PathwayREACTOME_EGR2_AND_SOX10_MEDIATED_INITIATION_OF_SCHWANN_CELL_MYELINATION

SREBF2 ADGRG6

1.14e-042982M29808
PathwayREACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP

SREBF2 CHD9

2.40e-044282M27172
PathwayREACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS

CHD9 HCFC1

4.12e-045582M27145
PathwayREACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF

SREBF2 CHD9

4.12e-045582M27001
PathwayREACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION

SREBF2 CHD9

9.60e-048482M1008
PathwayREACTOME_MITOCHONDRIAL_BIOGENESIS

CHD9 HCFC1

1.25e-039682M26973
PathwayREACTOME_ADIPOGENESIS

SREBF2 CHD9

1.64e-0311082M48259
PathwayREACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA

SREBF2 CHD9

1.88e-0311882M27316
PathwayREACTOME_METABOLISM_OF_STEROIDS

SREBF2 CHD9

3.18e-0315482M27832
PathwayREACTOME_DEVELOPMENTAL_BIOLOGY

SREBF2 TRIM33 ADGRG6 CHD9

5.31e-03143284M509
Pubmed

Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1.

ATF1 MUC2

2.73e-07311216227528
Pubmed

Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.

TRIM33 CHD9 NELFA HCFC1

5.15e-0722211437071664
Pubmed

A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening.

SREBF2 HCFC1

8.26e-061411210976766
Pubmed

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.

ATF1 TRIM33 CHD9 NELFA HCFC1

8.33e-06101411532416067
Pubmed

BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors.

TRIM33 NELFA HCFC1

9.02e-0613411325452129
Pubmed

PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.

ATF1 TRIM33 CHD9 NELFA HCFC1

1.25e-05110311534189442
Pubmed

Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.

TRIM33 NELFA HCFC1

7.13e-0526811333640491
Pubmed

An atlas of combinatorial transcriptional regulation in mouse and man.

SREBF2 MLLT10 NELFA HCFC1

1.15e-0487711420211142
Pubmed

MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.

TRIM33 NELFA HCFC1

1.43e-0433911330415952
Pubmed

A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency.

NELFA HCFC1

1.65e-046111220305087
Pubmed

Identification of proximal SUMO-dependent interactors using SUMO-ID.

TRIM33 NELFA HCFC1

3.16e-0444411334795231
GeneFamilyPHD finger proteins

TRIM33 MLLT10

5.06e-04907288
CoexpressionGSE13411_PLASMA_CELL_VS_MEMORY_BCELL_DN

TRIM33 CHD9 NELFA

6.60e-05197113M3255
CoexpressionLINDGREN_BLADDER_CANCER_CLUSTER_3_DN

ADGRG6 CHD9 MLLT10

9.92e-05226113M11238
CoexpressionKRASNOSELSKAYA_ILF3_TARGETS_DN

SREBF2 HCFC1

1.64e-0446112M12166
CoexpressionHOFMANN_CELL_LYMPHOMA_UP

ATF1 MLLT10

1.79e-0448112M10783
ToppCellkidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

ADGRG6 CHD9 MLLT10

1.37e-05199113174f6013af6eafa577f84205a62927f2b367fda3
ToppCellTCGA-Peripheral_Nervous_System-Primary_Tumor-Paraganglioma-Paraganglioma-3|TCGA-Peripheral_Nervous_System / Sample_Type by Project: Shred V9

ATF1 CHD9

4.83e-04135112ac20133d4a36f48338b45bffb13e842cb66f83ad
ToppCell390C-Fibroblasts-Fibroblast-B_(Myofibroblast)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

ADGRG6 MLLT10

6.77e-04160112cb8d0dc1a6c69c7a85c5fdd8f0f6cca1b73dfc63
ToppCell390C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

ADGRG6 MLLT10

6.77e-04160112636127753e3a22831f39d4c8170df40901e4329d
ToppCell10x_3'_v3-blood_(10x_3'_v3)-myeloid-myeloid_dendritic|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

MUC2 ADGRG6

6.94e-04162112233011408f022647932c81ebab78f9813e3c6833
ToppCell5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

MLLT10 HCFC1

8.74e-0418211253213af34af3337f5edc734d3b7b79e4349eac0d
ToppCell5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular-Interstitial_macrophage_perivascular_L.1.2.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

MLLT10 HCFC1

8.74e-041821127909089ed6325c44edd6f9b7e8b1d542398222ea
ToppCell5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

MLLT10 HCFC1

8.74e-041821124a85429d365c4b2d73fc921f261b4b7635ac40bd
ToppCellFetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SREBF2 ADGRG6

9.32e-0418811243a3a59f92ad93509d4166bd025aed0b1b39a008
ToppCellrenal_papilla_nuclei-Adult_normal_reference|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group

SREBF2 CHD9

9.72e-041921126c106b91e46eabbe686a52a65a9c94ad9cbe9390
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

SREBF2 CHD9

9.82e-0419311208696a99309f5b088692ddac8cca35413b5e810d
ToppCellTCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6|TCGA-Prostate / Sample_Type by Project: Shred V9

USF3 TRIM33

9.82e-04193112abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Newborn-35|World / Primary Cells by Cluster

TRIM33 CHD9

1.03e-03198112de5214a85fe017eb23d4aa8af624464f062ec57e
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 ADGRG6 MLLT10

7.04e-051751134072_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ADGRG6 MLLT10 HCFC1

7.65e-051801133688_DN
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A

SREBF2 ADGRG6 CHD9

8.71e-051881134845_DN
DrugResveratrol [501-36-0]; Up 200; 17.6uM; HL60; HG-U133A

MUC2 MLLT10 HCFC1

9.41e-051931131715_UP
DrugOxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; HL60; HG-U133A

ATF1 TRIM33 CHD9

9.70e-051951131431_DN
Drugestradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA

SREBF2 MLLT10 HCFC1

9.85e-051961131021_DN
DrugFlurandrenolide [1524-88-5]; Up 200; 9.2uM; PC3; HT_HG-U133A

SREBF2 ADGRG6 HCFC1

9.85e-051961137378_UP
DrugFenspiride hydrochloride [5053-08-7]; Down 200; 13.4uM; HL60; HG-U133A

ATF1 CHD9 NELFA

9.85e-051961131422_DN
DrugAdiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; HL60; HT_HG-U133A

TRIM33 CHD9 MLLT10

9.85e-051961131872_UP
DrugAjmalicine hydrochloride [4373-34-6]; Down 200; 10.2uM; PC3; HT_HG-U133A

SREBF2 MLLT10 HCFC1

1.00e-041971136360_DN
DrugEthamsylate [2624-44-4]; Down 200; 15.2uM; HL60; HT_HG-U133A

SREBF2 TRIM33 NELFA

1.00e-041971132915_DN
DrugMepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A

SREBF2 TRIM33 HCFC1

1.00e-041971133748_DN
DrugAG-013608 [351320-38-2]; Up 200; 10uM; PC3; HT_HG-U133A

SREBF2 MLLT10 HCFC1

1.00e-041971136440_UP
DrugTodralazine hydrochloride [3778-76-5]; Down 200; 14.8uM; PC3; HT_HG-U133A

SREBF2 TRIM33 MLLT10

1.00e-041971135087_DN
DrugVancomycin hydrochloride [1404-93-9]; Up 200; 2.6uM; MCF7; HT_HG-U133A

SREBF2 TRIM33 MLLT10

1.00e-041971132858_UP
DrugPanthenol (D) [81-13-0]; Down 200; 19.4uM; MCF7; HT_HG-U133A

TRIM33 MLLT10 HCFC1

1.00e-041971131680_DN
DrugBAS 012416453; Up 200; 38uM; MCF7; HT_HG-U133A

ATF1 ADGRG6 MLLT10

1.00e-041971136908_UP
DrugMorantel tartrate [26155-31-7]; Down 200; 10.8uM; MCF7; HT_HG-U133A

SREBF2 MLLT10 HCFC1

1.02e-041981137010_DN
DrugMethiothepin maleate [19728-88-2]; Down 200; 8.4uM; PC3; HT_HG-U133A

SREBF2 TRIM33 HCFC1

1.03e-041991136312_DN
DrugTinidazole [19387-91-8]; Down 200; 16.2uM; MCF7; HT_HG-U133A

SREBF2 MLLT10 HCFC1

1.03e-041991133430_DN
Drugp-hydroxymandelonitrile

ATF1 MLLT10

1.40e-03117112CID000166768
Drugirinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A

TRIM33 CHD9

2.95e-031711127535_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

ADGRG6 HCFC1

2.98e-031721127073_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.02e-031731122084_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.02e-031731124565_DN
Drugirinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A

TRIM33 CHD9

3.05e-031741127530_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.05e-031741127105_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

ADGRG6 HCFC1

3.09e-031751125908_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.09e-031751126316_DN
DrugSAHA; Down 200; 10uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.09e-031751121220_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 HCFC1

3.23e-031791125822_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 MLLT10

3.23e-031791124483_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A

TRIM33 CHD9

3.26e-031801124541_DN
DrugCycloheximide [66-81-9]; Down 200; 14.2uM; PC3; HT_HG-U133A

SREBF2 HCFC1

3.30e-031811125743_DN
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; PC3; HT_HG-U133A

MUC2 HCFC1

3.33e-031821126663_UP
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

TRIM33 CHD9

3.33e-031821123887_DN
DrugTiclopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; MCF7; HT_HG-U133A

SREBF2 HCFC1

3.37e-031831121475_UP
Drugirinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A

TRIM33 CHD9

3.37e-031831127498_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

TRIM33 CHD9

3.41e-031841122321_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ATF1 ADGRG6

3.44e-031851125882_DN
DrugLY 294002; Up 200; 10uM; PC3; HT_HG-U133A

TRIM33 ADGRG6

3.48e-031861124463_UP
Drugfluphenazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A

SREBF2 MLLT10

3.48e-031861126996_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

TRIM33 MLLT10

3.48e-03186112916_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

MLLT10 HCFC1

3.48e-031861126874_DN
DrugThioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A

TRIM33 HCFC1

3.51e-031871124989_DN
Drugtrichostatin A; Down 200; 0.1uM; PC3; HG-U133A

ATF1 MUC2

3.51e-03187112448_DN
DrugMebendazole [31431-39-7]; Up 200; 13.6uM; PC3; HT_HG-U133A

SREBF2 HCFC1

3.55e-031881127370_UP
DrugChlorpromazine hydrochloride [69-09-0]; Up 200; 11.2uM; MCF7; HT_HG-U133A

MLLT10 HCFC1

3.55e-031881125493_UP
Drugikarugamycin; Up 200; 2uM; MCF7; HT_HG-U133A_EA

MLLT10 HCFC1

3.55e-03188112974_UP
DrugPromethazine hydrochloride [58-33-3]; Down 200; 12.4uM; PC3; HT_HG-U133A

SREBF2 MLLT10

3.59e-031891126717_DN
DrugThioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A

SREBF2 TRIM33

3.63e-031901122619_DN
DrugSulconazole nitrate [61318-91-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A

TRIM33 HCFC1

3.63e-031901123373_DN
Drugresveratrol; Down 200; 50uM; MCF7; HG-U133A

ADGRG6 HCFC1

3.63e-03190112622_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

ADGRG6 MLLT10

3.63e-031901126709_DN
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

ADGRG6 HCFC1

3.63e-031901127528_DN
DrugEthopropazine hydrochloride [1094-08-2]; Up 200; 11.4uM; MCF7; HT_HG-U133A

MLLT10 HCFC1

3.66e-031911125296_UP
DrugCP-944629 [668990-94-1]; Down 200; 10uM; PC3; HT_HG-U133A

MLLT10 HCFC1

3.66e-031911127549_DN
Drugretinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA

SREBF2 MLLT10

3.66e-03191112991_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

MLLT10 HCFC1

3.66e-031911125567_DN
DrugEstriol [50-27-1]; Down 200; 13.8uM; MCF7; HT_HG-U133A

ADGRG6 HCFC1

3.66e-031911127220_DN
DrugGuanfacine hydrochloride [29110-48-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A

SREBF2 HCFC1

3.66e-031911122634_DN
DrugDipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A

SREBF2 HCFC1

3.70e-031921123929_DN
DrugTriprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; PC3; HT_HG-U133A

NELFA HCFC1

3.70e-031921127248_UP
Drugwortmannin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

TRIM33 CHD9

3.70e-03192112977_DN
DrugHesperidin [520-26-3]; Down 200; 6.6uM; PC3; HT_HG-U133A

TRIM33 MLLT10

3.70e-031921126714_DN
DrugDimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A

MUC2 HCFC1

3.70e-031921122807_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A

ATF1 HCFC1

3.70e-031921121971_DN
DrugCaffeic acid [3331-39-5]; Down 200; 22.2uM; PC3; HT_HG-U133A

SREBF2 MLLT10

3.74e-031931126753_DN
DrugTalampicillin hydrochloride [39878-70-1]; Down 200; 7.8uM; MCF7; HT_HG-U133A

TRIM33 MLLT10

3.74e-031931127014_DN
Drug15d-PGJ2; Up 200; 10uM; MCF7; HG-U133A

MUC2 CHD9

3.74e-03193112201_UP
DrugQuercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A

SREBF2 HCFC1

3.74e-031931124846_DN
DrugHexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; HL60; HG-U133A

ATF1 HCFC1

3.74e-031931121982_DN
Drugaspirin, USP; Down 200; 100uM; MCF7; HT_HG-U133A

MLLT10 HCFC1

3.74e-031931126964_DN
DrugCP-320650-01 [172079-28-6]; Down 200; 1uM; MCF7; HT_HG-U133A

NELFA HCFC1

3.74e-031931123908_DN
DrugForskolin, from Coleus forskohlii; Down 200; 0.5uM; PC3; HT_HG-U133A

MLLT10 HCFC1

3.74e-031931127059_DN
DrugCeforanide [60925-61-3]; Down 200; 7.6uM; PC3; HT_HG-U133A

ADGRG6 MLLT10

3.74e-031931126751_DN
DrugPentolinium bitartrate [52-62-0]; Down 200; 7.4uM; PC3; HT_HG-U133A

SREBF2 TRIM33

3.74e-031931127375_DN
Drug5114445; Down 200; 10uM; MCF7; HT_HG-U133A_EA

TRIM33 HCFC1

3.74e-03193112901_DN
DrugSulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; PC3; HT_HG-U133A

SREBF2 MLLT10

3.74e-031931121817_UP
Drugtrichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A

TRIM33 MLLT10

3.74e-03193112413_DN
DrugMuramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

SREBF2 HCFC1

3.74e-031931123262_UP
DrugLynestrenol [52-76-6]; Down 200; 14uM; PC3; HT_HG-U133A

ADGRG6 MLLT10

3.78e-031941126756_DN
DrugRapamycin; Down 200; 0.1uM; PC3; HT_HG-U133A

SREBF2 HCFC1

3.78e-031941121221_DN
DrugAzaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A

TRIM33 HCFC1

3.78e-031941121670_DN
DrugNadide [53-84-9]; Up 200; 6uM; PC3; HT_HG-U133A

SREBF2 MLLT10

3.78e-031941125873_UP
Drug2-propylpentanoic acid; Down 200; 1000uM; PC3; HT_HG-U133A

SREBF2 ATF1

3.78e-031941121209_DN
DrugGly-His-Lys acetate salt; Down 200; 1uM; MCF7; HT_HG-U133A

SREBF2 MLLT10

3.78e-031941126575_DN
DrugPyrilamine maleate [59-33-6]; Up 200; 10uM; PC3; HT_HG-U133A

MLLT10 HCFC1

3.78e-031941125869_UP
Diseasecongenital heart disease (implicated_via_orthology)

CHD9 HCFC1

2.92e-0469112DOID:1682 (implicated_via_orthology)
Diseasebirth weight, parental genotype effect measurement

USF3 ADGRG6

2.23e-03192112EFO_0004344, EFO_0005939
Diseaseneuroimaging measurement, brain volume measurement

ATF1 MLLT10

4.86e-03286112EFO_0004346, EFO_0006930
Diseasewhite matter microstructure measurement

ADGRG6 MLLT10

8.86e-03390112EFO_0005674
Diseasebirth weight

SREBF2 ADGRG6

9.25e-03399112EFO_0004344
Diseasebrain connectivity measurement

ATF1 MLLT10

9.30e-03400112EFO_0005210
Diseasebody weight

USF3 ADGRG6 MLLT10

9.93e-031261113EFO_0004338
Diseaseneutrophil count

TRIM33 ADGRG6 CHD9

1.27e-021382113EFO_0004833

Protein segments in the cluster

PeptideGeneStartEntry
STTPPTVTTNMPVTN

ADGRG6

386

Q86SQ4
TPTITMQPVSQPTQV

HCFC1

946

P51610
MQPVSQPTQVTLITA

HCFC1

951

P51610
TTQTPPVAMVAPQTQ

NELFA

406

Q9H3P2
QPTTMTTTTTENPTP

MUC2

1881

Q02817
IQQIQPTFSVPTSVM

CHD9

1801

Q3L8U1
QPIMNPTVQQQVPTS

KIAA1210

916

Q9ULL0
MQQPPAPVPTTTTTT

TRIM33

536

Q9UPN9
QTPVTMSQNPTPLTH

MLLT10

921

P55197
PQTVVMTSPVTLTSQ

ATF1

191

P18846
PQTQLQQQTVMITPT

SREBF2

141

Q12772
QQQTVMITPTFSTTP

SREBF2

146

Q12772
GTTNQTPMQIIQPTT

USF3

681

Q68DE3